ScholarLens Back to search
2010•The American Journal of GastroenterologyRequires access

The Efficacy of Rebamipide on Endoscopical, Histopathological Severity and Free Radicals in Chronic Gastritis

Marcellus Simadibrata, Ari Fahrial Syam, Abdul Aziz Rani, Septelia Inawati Wanandi, Murdani Abdullah, Achmad Fauzi, Diah Rini Handjari

Open publisher page 0 citations

Abstract

Purpose: Free radicals have a role in the development of chronic gastritis. The aim of this study to know the effect and efficacy of Rebamipide on free radicals in chronic gastritis. Methods: Forty one patients in the Division of Gastroenterology, Dr Cipto Mangunkusumo Hospital Jakarta 2009-2010 with moderate and severe gastritis endoscopically were included in this study. Before and after Rebamipide treatment the patient were performed endoscopical examination and were taken 5 biopsies for histopathological examination and free radicals (MDA & Carbonyl Compound) examination. All patients were given Rebamipide 3 x 100 mg/day for 28 days. Data were analyzed with paired t test. Exclusion: GERD, Peptic ulcer, PPI treatment, NSAID consumption. Results: The most frequent characteristic was male (51.2%), age 42.44+/11.72 years old. The mean+/SD score of mucosal damage on day 0 was 2.268+/0.448 vs. day 28 was 1.707+/0.782 (p<0.001). The mean+/SD antrum neutrophil: day 0: 0.122+/0.458 vs. day 28: 0.097+/0.375 and mean+/SD corpus neutrophil: day 0: 0.122+/0.399 vs. day 28: 0.073+/0.264. Rebamipide can reduce the mean level of MDA from 5.617 +/ 3.544 nmol/mg protein on day 0 to 4.498 +/ 2.709 nmol/mg protein on day 28 (p=0.047). The mean of carbonyl compound on day 0 was 4.949 +/ 3.009 umol/mg protein and on day 28 was 5.201 +/ 2.828 umol/mg protein (p=0.642). Conclusion: Rebamipide can reduce the mucosal damage and the MDA level in chronic gastritis. This research was supported by an industry grant from PT. Otsuka Indonesia.

About this research paper

What this paper is about

Purpose: Free radicals have a role in the development of chronic gastritis. The aim of this study to know the effect and efficacy of Rebamipide on free radicals in chronic gastritis. Methods: Forty one patients in the Division of Gastroenterology, Dr Cipto Mangunkusumo Hospital Jakarta 2009-2010 with moderate and severe gastritis endoscopically were included in this study. Before and after Rebamipide treatment the patient were performed endoscopical examination and were taken 5 biopsies for histopathological examination and free radicals (MDA & Carbonyl Compound) examination. All patients were given Rebamipide 3 x 100 mg/day for 28 days. Data were analyzed with paired t test. Exclusion: GERD, Peptic ulcer, PPI treatment, NSAID consumption. Results: The most frequent characteristic was male (51.2%), age 42.44+/11.72 years old. The mean+/SD score of mucosal damage on day 0 was 2.268+/0.448 vs. day 28 was 1.707+/0.782 (p<0.001). The mean+/SD antrum neutrophil: day 0: 0.122+/0.458 vs. day 28: 0.097+/0.375 and mean+/SD corpus neutrophil: day 0: 0.122+/0.399 vs. day 28: 0.073+/0.264. Rebamipide can reduce the mean level of MDA from 5.617 +/ 3.544 nmol/mg protein on day 0 to 4.498 +/ 2.709 nmol/mg protein on day 28 (p=0.047). The mean of carbonyl compound on day 0 was 4.949 +/ 3.009 umol/mg protein and on day 28 was 5.201 +/ 2.828 umol/mg protein (p=0.642). Conclusion: Rebamipide can reduce the mucosal damage and the MDA level in chronic gastritis. This research was supported by an industry grant from PT. Otsuka Indonesia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Purpose: Free radicals have a role in the development of chronic gastritis. The aim of this study to know the effect and efficacy of Rebamipide on free radicals in chronic gastritis. Methods: Forty one patients in the Division of Gastroenterology, Dr Cipto Mangunkusumo Hospital Jakarta 2009-2010 with moderate and severe gastritis endoscopically were included in this study. Before and after Rebamipide treatment the patient were performed endoscopical examination and were taken 5 biopsies for histopathological examination and free radicals (MDA & Carbonyl Compound) examination. All patients were given Rebamipide 3 x 100 mg/day for 28 days. Data were analyzed with paired t test. Exclusion: GERD, Peptic ulcer, PPI treatment, NSAID consumption. Results: The most frequent characteristic was male (51.2%), age 42.44+/11.72 years old. The mean+/SD score of mucosal damage on day 0 was 2.268+/0.448 vs. day 28 was 1.707+/0.782 (p<0.001). The mean+/SD antrum neutrophil: day 0: 0.122+/0.458 vs. day 28: 0.097+/0.375 and mean+/SD corpus neutrophil: day 0: 0.122+/0.399 vs. day 28: 0.073+/0.264. Rebamipide can reduce the mean level of MDA from 5.617 +/ 3.544 nmol/mg protein on day 0 to 4.498 +/ 2.709 nmol/mg protein on day 28 (p=0.047). The mean of carbonyl compound on day 0 was 4.949 +/ 3.009 umol/mg protein and on day 28 was 5.201 +/ 2.828 umol/mg protein (p=0.642). Conclusion: Rebamipide can reduce the mucosal damage and the MDA level in chronic gastritis. This research was supported by an industry grant from PT. Otsuka Indonesia.

Key concepts: Rebamipide, Medicine, Gastroenterology, Internal medicine, Gastritis, Chronic gastritis, Stomach

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
The Efficacy of Rebamipide on Endoscopical, Histopathological Severity and Free Radicals in Chronic Gastritis — Research Paper | ScholarLens